Drug costs developments after patent expiry of enalapril, fluoxetine and ranitidine: A study conducted for the Netherlands

Applied Health Economics and Health Policy

Volumn 4, Issue 3, 2005, Pages 191-196

  Boersma, Cornelis ^a,b   Klok, Rogier M ^a   Bos, Jasper M ^a   Naunton, Mark ^a   Van Den Berg, Paul B ^a   De Jongvan Den Berg, Lolkje T W ^a   Postma, Maarten J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b NONE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ENALAPRIL; FLUOXETINE; RANITIDINE;

ARTICLE; CALCULATION; DATA ANALYSIS; DRUG COST; DRUG MARKETING; GOVERNMENT; HUMAN; NETHERLANDS; PHARMACY;

ANTI-ULCER AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIHYPERTENSIVE AGENTS; DRUG COSTS; DRUGS, GENERIC; ENALAPRIL; FLUOXETINE; HUMANS; NETHERLANDS; PATENTS AS TOPIC; RANITIDINE; REIMBURSEMENT MECHANISMS;

EID: 28444458070     PISSN: 11755652     EISSN: 11755652     Source Type: Journal    
DOI: 10.2165/00148365-200504030-00008     Document Type: Article

References (17)

1. Canton E, Westerhout E. A model for the Dutch pharmaceutical market. Health Econ 1999; 8: 391-402
2. Werkö L. The rapidly increasing cost of medicines threatens the core of healthcare. Scand Cardiovasc J 2004; 38: 130-1
3. López-Casanovas G, Puig-Junoy J. Review of the literature on reference pricing. Health Policy 2000; 54: 87-123
4. Ess SM, Schneeweiss S, Szucs TD. European healthcare policies for controlling drug expenditure. Pharmacoeconomics 2003; 21 (2): 89-103
5. Garattini L, Tediosi F. A comparative analysis of generics markets in five European countries. Health Policy 2000; 51 (3): 149-62
6. Vogel RJ. Pharmaceutical pricing, price controls, and their effects on pharmaceutical sales and research and development expenditures in the European Union. Clin Ther 2004; 26 (8): 1327-40
7. Mrazek MF. Comparative approaches to pharmaceutical price regulation in the European Union. Croat Med J 2002; 43 (4): 453-61
8. Magazzini L, Pammolli F, Riccaboni M. Dynamic competition in pharmaceuticals: patent expiry, generic penetration, and industry structure. Eur J Health Econ 2004; 5: 175-82
9. King DR, Kanavos P. Encouraging the use of generic medicines: implications for transition economies. Croat Med J 2002; 43 (4): 462-9
10. Pronk MH, Bonsel GJ, van der Kuy A. The budget control function of the drug reimbursement system. Ned Tijdschr Geneeskd 2002; 146 (37): 1729-33
11. Tobi H, Van den Berg PB, De Jong-van den Berg LTW. The InterAction Database: synergy of science and practice in pharmacy. In: Brause RW, Hanisch E, editors. Medical data analysis. Berlin: Springer-Verlag, 2000: 206-11
12. Schirm E, Monster TBM, De Vries R, et al. How to estimate the population that is covered by community pharmacies? An evaluation of two methods using the drug utilisation information. Pharmacoepidemiol Drug Saf 2004; 13: 173-9
13. Official Dutch drug prices: G-standard of Z-index, The Hague 12/2001 [in Dutch]. Z-index [online]. Available at URL: http://www.z-index.nl [Accessed 2005 Oct 31]
14. Tinke JL. Increasing use of gastric acid inhibitors [in Dutch]. Pharm Weekbl 2001; 136 (20): 701
15. Huttin C. Experiences with reference pricing. Int J Risk Saf Med 2002; 15: 85-91
16. Lexchin J. The effect of generic competition on the price of brand-name drugs. Health Policy 2004; 68: 47-54
17. Nuijten MJC, Berto P, Berdeaux G, et al. Trends in decision-making process for pharmaceuticals in Western European countries: a focus on emerging hurdles for obtaining reimbursement and a price. Health Econ Prev Care 2001; 2 (4): 162-9